abstract |
The present invention relates to the use of a TLR7 agonist, 2-butoxy-7- (4- (pyrrolidin-l-ylmethyl) -benzyl) -5H- pyrrolo [3,2- d] pyrimidin- ), A crystalline form B of trifluoroacetate, a process for producing said trifluoroacetate and crystalline Form B, and the use of said trifluoroacetate and crystalline Form B. |